Royal Bank of Canada
UTHR icon

Royal Bank of Canada’s United Therapeutics UTHR Stock Holding History

Royal Bank of Canada’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.9M Buy
62,600
+3,448
+6% +$1.94M 0.01% 1228
2026
Q1 		$35.1M Buy
59,152
+1,864
+3% +$928K 0.01% 1111
2025
Q4 		$27.9M Buy
57,288
+20,856
+57% +$9.71M ﹤0.01% 1265
2025
Q3 		$15.3M Sell
36,432
-72,636
-67% -$24.4M ﹤0.01% 1866
2025
Q2 		$31.3M Buy
109,068
+43,279
+66% +$12.9M 0.01% 1209
2025
Q1 		$20.3M Buy
65,789
+32,867
+100% +$11.3M ﹤0.01% 1293
2024
Q4 		$11.6M Sell
32,922
-2,666
-7% -$980K ﹤0.01% 1704
2024
Q3 		$12.8M Buy
35,588
+759
+2% +$256K ﹤0.01% 1633
2024
Q2 		$11.1M Sell
34,829
-5,557
-14% -$1.47M ﹤0.01% 1614
2024
Q1 		$9.28M Buy
40,386
+8,963
+29% +$2.02M ﹤0.01% 1722
2023
Q4 		$6.91M Buy
31,423
+17,881
+132% +$4.12M ﹤0.01% 2007
2023
Q3 		$3.06M Buy
13,542
+2,815
+26% +$648K ﹤0.01% 2486
2023
Q2 		$2.37M Buy
10,727
+1,515
+16% +$336K ﹤0.01% 2709
2023
Q1 		$2.06M Sell
9,212
-6,578
-42% -$1.62M ﹤0.01% 2771
2022
Q4 		$4.39M Sell
15,790
-6,859
-30% -$1.73M ﹤0.01% 2247
2022
Q3 		$4.74M Buy
22,649
+1,690
+8% +$378K ﹤0.01% 2110
2022
Q2 		$4.94M Sell
20,959
-2,275
-10% -$463K ﹤0.01% 2114
2022
Q1 		$4.17M Sell
23,234
-13,097
-36% -$2.5M ﹤0.01% 2408
2021
Q4 		$7.85M Buy
36,331
+9,910
+38% +$1.95M ﹤0.01% 2056
2021
Q3 		$4.88M Buy
26,421
+3,279
+14% +$646K ﹤0.01% 2311
2021
Q2 		$4.15M Buy
23,142
+4,176
+22% +$795K ﹤0.01% 2445
2021
Q1 		$3.17M Sell
18,966
-702
-4% -$117K ﹤0.01% 2610
2020
Q4 		$2.99M Sell
19,668
-4,580
-19% -$601K ﹤0.01% 2571
2020
Q3 		$2.45M Buy
24,248
+7,865
+48% +$863K ﹤0.01% 2520
2020
Q2 		$1.98M Sell
16,383
-1,391
-8% -$157K ﹤0.01% 2619
2020
Q1 		$1.69M Sell
17,774
-1,501
-8% -$143K ﹤0.01% 2612
2019
Q4 		$1.7M Sell
19,275
-5,082
-21% -$447K ﹤0.01% 3022
2019
Q3 		$1.94M Sell
24,357
-11,758
-33% -$947K ﹤0.01% 2788
2019
Q2 		$2.82M Buy
36,115
+4,190
+13% +$392K ﹤0.01% 2503
2019
Q1 		$3.75M Sell
31,925
-8,750
-22% -$1.02M ﹤0.01% 2226
2018
Q4 		$4.43M Sell
40,675
-21,954
-35% -$2.55M ﹤0.01% 2079
2018
Q3 		$7.97M Buy
62,629
+11,599
+23% +$1.43M ﹤0.01% 1765
2018
Q2 		$5.77M Sell
51,030
-66,411
-57% -$7.3M ﹤0.01% 1911
2018
Q1 		$13.2M Sell
117,441
-102,676
-47% -$13M 0.01% 1355
2017
Q4 		$32.6M Sell
220,117
-8,172
-4% -$1.04M 0.01% 833
2017
Q3 		$26.8M Buy
228,289
+165,234
+262% +$21.1M 0.01% 918
2017
Q2 		$8.18M Buy
63,055
+31,776
+102% +$3.96M ﹤0.01% 1635
2017
Q1 		$4.24M Sell
31,279
-2,610
-8% -$395K ﹤0.01% 2027
2016
Q4 		$4.86M Buy
33,889
+4,373
+15% +$558K ﹤0.01% 1964
2016
Q3 		$3.48M Sell
29,516
-62,766
-68% -$7.54M ﹤0.01% 2155
2016
Q2 		$9.77M Sell
92,282
-17,689
-16% -$1.97M 0.01% 1474
2016
Q1 		$12.3M Buy
109,971
+39,964
+57% +$5.06M 0.01% 1259
2015
Q4 		$11M Sell
70,007
-3,932
-5% -$572K 0.01% 1371
2015
Q3 		$9.7M Buy
73,939
+45,625
+161% +$7.32M 0.01% 1172
2015
Q2 		$4.93M Sell
28,314
-12,859
-31% -$2.31M ﹤0.01% 1613
2015
Q1 		$7.1M Sell
41,173
-21,799
-35% -$3.32M 0.01% 1388
2014
Q4 		$8.15M Sell
62,972
-8,925
-12% -$1.15M 0.01% 1338
2014
Q3 		$9.25M Sell
71,897
-38,294
-35% -$3.95M 0.01% 1247
2014
Q2 		$9.75M Buy
110,191
+14,927
+16% +$1.44M 0.01% 1240
2014
Q1 		$8.96M Buy
95,264
+4,139
+5% +$423K 0.01% 1224
2013
Q4 		$10.3M Sell
91,125
-84,194
-48% -$7.59M 0.01% 1174
2013
Q3 		$13.8M Buy
175,319
+17,354
+11% +$1.27M 0.01% 945
2013
Q2 		$10.4M Buy
+157,965
New +$10.2M 0.01% 1014

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Royal Bank of Canada's UTHR Position: Q2 2026 in Review

Royal Bank of Canada increased its United Therapeutics (UTHR) stake by 5.8% in Q2 2026, buying an estimated $1.94M and bringing the position to 62,600 shares worth $33.9M. The position accounts for 0.01% of the portfolio, ranked #1228.

Royal Bank of Canada first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $35.1M in Q1 2026. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Royal Bank of Canada held 62,600 shares of United Therapeutics worth $33.9M as of Q2 2026.
  • Royal Bank of Canada bought 3,448 United Therapeutics shares in Q2 2026, an estimated $1.94M.
  • United Therapeutics made up 0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #1228 holding.
  • Royal Bank of Canada first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Royal Bank of Canada's United Therapeutics position peaked at $35.1M in Q1 2026.
  • 874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.